ALKS Alkermes plc
ALKS Alkermes plc
Healthcare · Drug Manufacturers - Specialty & Generic
Market read
POC $28.79 · VWAP $37.22 · +10.8% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster EVP, Director + 1 other sold $2.8M, Aug 3
Coverage
1 watchlist
ALKS Price Structure
Loading timeframes…
Peers
Every watchlist ALKS belongs to, members best 30-day change first — ALKS highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-06-30: revenue $496M, diluted EPS $0.00, net income $501000 (SEC filing). Across the print the stock moved -8.3% (close before → first close after).
full note →Against street estimates
How ALKS's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
ALKS research tape
37 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.